Clinical Trial Update: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis [Phase 2]

View source ↗

Summary

Open-label extension study to assess long-term safety and efficacy of ESK-001 in plaque psoriasis (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ESK-001

Snippet

Sponsor: Alumis Inc | Conditions: Plaque Psoriasis | Phase 2 | Status: ACTIVE_NOT_RECRUITING